reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TGTX TG THERAPEUTICS INC.
OSUR ORASURE TECHNOLOGIES INC.
HBI HANESBRANDS INC.
CMTL COMTECH TELECOMMUNICATIONS CORP.
CENX CENTURY ALUMINUM COMPANY
PVH PVH CORP.
RL RALPH LAUREN CORPORATION CLASS A
AA ALCOA CORPORATION
RETA REATA PHARMACEUTICALS INC. CLASS A
UAA UNDER ARMOUR INC. CLASS A
RCKT ROCKET PHARMACEUTICALS
NINE NINE ENERGY SERVICE INC
A2H9KJ NEO PERFORMANCE MATERIAL
MEC MAYVILLE ENGINEERING
CPRI CAPRI HOLDINGS LIMITED
TXG 10X GENOMICS INC CLASS A
INMD INMODE
ETNB 89BIO
GRWG GROWGENERATION
MGNI MAGNITE INC
FDMT 4D MOLECULAR THERAPEUTICS
SAM ATELIER DU MEUBLE INTERIEURS SA
PTRA PROTERRA INC
SGHT SIGHT SCIENCES INC
INDI INDIE SEMICONDUCTOR INC
ZIMVV ZIMVIE INC
EMBC EMBECTA CORP
RCEL AVITA MEDICAL INC
- Jonathan Moreland
SUP SUPERIOR INDUSTRIES INTERNATIONAL INC.
RDUS RADIUS HEALTH INC.
NHI NATIONAL HEALTH INVESTORS INC.
MIXT MIX TELEMATICS ADR
MACK MERRIMACK PHARMACEUTICALS INC
LNDC LANDEC CORP.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CPSS CONSUMER PORTFOLIO SERVICES INC.
CPRX CATALYST PHARMACEUTICALS
CODI COMPASS DIVERSIFIED HOLDINGS
CLRO CLEARONE
ANGO ANGIODYNAMICS INC.
NEWT NEWTEK BUSINESS SERVICES INC.
RAIN RAIN INDUSTRIES LIMITED
BBBY BED BATH & BEYOND INC.
NX QUANEX BUILDING PRODUCTS CORPORATION
THO THOR INDUSTRIES INC.
CZNC CITIZENS & NORTHERN CORP.
RETA REATA PHARMACEUTICALS INC. CLASS A
MTEM MOLECULAR TEMPLATES
MRSN MERSANA THERAPEUTICS
RGCO RGC RESOURCES
CDLX CARDLYTICS INC
SFIX STITCH FIX CLASS A
RNDB RANDOLPH BANCORP
LAZY LAZYDAYS HOLDINGS
RXMD PROGRESSIVE CARE INC
OSAT ORBITAL TRACKING CORP
ANIX ANIXA BIOSCIENCES
ALLO ALLOGENE THERAPEUTICS
LBSRD LIBERTY STAR URANIUM & METALS
SLGG SUPER LEAGUE GAMING
PHR PHREESIA
MRBK MERIDIAN
EMPRD EMPIRE PETROLEUM CORP.
PASG PASSAGE BIO
ASO INC.
ASAN ACADEMY SPORTS AND OUTDOORS
BDSX ASANA
TURN BIODESIX
WOOF 180 DEGREE CAPITAL
SNSE PETCO HEALTH AND WELLNESS
PTPI SENSEI BIOTHERAPEUTICS
FORA PETROS PHARMACEUTICALS
MJNE INC.
RICK FORIAN INC
VIRI MJ HOLDINGS
AVTX INC.
RLYB RICK'S CABARET INTERNATIONAL
INC.
VIRIOS THERAPEUTICS LLC
AVALO THERAPEUTICS INC
RALLYBIO CORP
An unfavourable environment weighs on REATA PHARMAC, which sees a down...
The independent financial analyst theScreener just requalified the general evaluation of REATA PHARMAC (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date January 11, 2022, the closing price was USD ...
- Jonathan Moreland
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
DRQ DRIL-QUIP INC.
RETA REATA PHARMACEUTICALS INC. CLASS A
MRSN MERSANA THERAPEUTICS
BAND BANDWIDTH CLASS A
PRPL PURPLE INNOVATION
AXR INC.
PHR AMREP
TELA PHREESIA
EMPRD TELA BIO
BDSX EMPIRE PETROLEUM CORP.
NRGX BIODESIX
PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
- Dave Nicoski
- Ross LaDuke
XONE EXONE CO
SPLK SPLUNK INC.
RUN SUNRUN INC.
RGNX REGENXBIO INC.
REGN REGENERON PHARMACEUTICALS INC.
NRG NRG ENERGY INC.
LXRX LEXICON PHARMACEUTICALS INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
K KELLOGG COMPANY
EDIT EDITAS MEDICINE INC.
CHMA CHIASMA
BMRN BIOMARIN PHARMACEUTICAL INC.
AXSM AXSOME THERAPEUTICS
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
PI IMPINJ INC.
RETA REATA PHARMACEUTICALS INC. CLASS A
TNDM TANDEM DIABETES CARE
APPN APPIAN
RGCO RGC RESOURCES
SAIL SAILPOINT TECHNOLOGIES
APLT APPLIED THERAPEUTICS
NOVA SUNNOVA ENERGY INTERNATIONAL
VERO VENUS CONCEPT
MGNI MAGNITE INC
PCVX VAXCYTE
U UNITY SOFTWARE
MAXN MAXEON SOLAR TECHNOLOGIES
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VOLT VOLT INFORMATION SCIENCES INC
TGL. TECNOGLASS INC.
RM REGIONAL MANAGEMENT CORP
PLCE CHILDREN'S PLACE INC.
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
MYGN MYRIAD GENETICS INC.
GMED GLOBUS MEDICAL INC CLASS A
EXPR EXPRESS INC.
EVC ENTRAVISION COMMUNICATIONS CORP.
DECK DECKERS OUTDOOR CORPORATION
CHS CHICO'S FAS INC.
APOG APOGEE ENTERPRISES INC.
VRS VERSO CORPORATIN
SEB MIEN TRUNG POWER INVESTMENT AND DEVELOPMENT
FSLR FIRST SOLAR INC.
GMS GMS INC.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
WHG WESTWOOD HOLDINGS GROUP INC.
OPOF OLD POINT FINANCIAL CORP.
RETA REATA PHARMACEUTICALS INC. CLASS A
ARNA ARENA PHARMACEUTICALS INC.
NKE NIKE INC. CLASS B
ATOS ATOSSA THERAPEUTICS
LWLG LIGHTWAVE LOGIC
UNB UNION BANKSHARES INC.
ATLC AL TAWFEEK LEASING
APO APOLLO GLOBAL MANAGEMENT INC. CLASS A
SPCE VIRGIN GALACTIC HOLDINGS (A)
FUBO FUBOTV
CDR CEDAR REALTY TRUST INC
OPCH OPTION CARE HEALTH INC
RNA AVIDITY BIOSCIENCES
AGFY AGRIFY
AMR ALPHA METALLURGICAL RESOURCES INC
CRCT CRICUT
BVS INC.
COMM BIOVENTUS
PSFE BMO GLOBAL COMMUNICATIONS INDEX ETF
PAYSAFE LTD.
Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42n...
Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and hold 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patien...
Reata Announces that The FDA Has Asked The Company to Request a Pre-ND...
Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it received a communication from the Division of Neurology Products 1 (“Division”) of the U.S. Food and Drug Administration (“FDA”) stating that, after a preliminary review of briefing materials for an upcoming Type C meeting, a pre-NDA meeting is the most appropria...
Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Res...
Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs ANNOUNCES FDA ACCEPTED FOR FILING REATA’S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME IF APPROVED, BARDOXOLONE MAY BECOME THE FIRST APPROVED THERAPY FOR ALPORT SYNDROME, A LIFE-THREATENING DISEASE THAT AFFECTS 30,000 – 60,000 PATIENTS IN THE U.S. REAFFIRMS ANTICIPATED COMPLETION OF ENROLLMENT BY END OF 2021 IN PHASE 3 FALCON TRIAL FOR ADPKD FDA GRANTED TYPE C MEETING TO DISCUSS FA DEVELOPMENT PROGRAM IN 2Q 2021 CONFIRM...
Reata Pharmaceuticals Announces Presentations at Upcoming Investor Con...
Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1x1 meetings at the following investor conferences: Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2021.Jefferies Virtual Healthcare Conference on June 2, 2021. About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel ...
Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials an...
Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021 PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on May 6, 2021. Reata’s management will host a conference call on May 6, 2021 at 8:30 am ET. The conference call will be accessible by dialing (866) 270-1533 (toll-...
Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for th...
Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies Application Assigned a PDUFA Date of February 25, 2022 If Approved, Bardoxolone Would Become the First Approved Therapy for Alport Syndrome in the United States PLANO, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinica...
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff ...
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021. “We are excited to welcome Ms. Ruff and Ms. Oliger to Reata’s board,” said Warren Huff, Reata’s Chief Executive Officer and President. “They join at a critical point in Reata’s development having just sub...
Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conf...
Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) will be presented at two upcoming nephrology conferences including The World Congress of Nephrology 2021 being held virtually from April 15 – 19, 2021 and the 58th European Renal Association and European Dialysis and Transplant Association (“ERA-EDT...
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 202...
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY’S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME PROVIDES UPDATE ON FALCON STUDY OF BARDOXOLONE IN ADPKD ANNOUNCES FIRST PATIENT ENROLLED IN MERLIN TRIAL OF BARDOXOLONE IN CHRONIC KIDNEY DISEASE AT RISK FOR RAPID PROGRESSION PROVIDES UPDATE ON NEUROLOGY PIPELINE CONFIRMS CASH RUNWAY THROUGH MID-2024 CONFERENCE CALL WITH MANAGEMENT ON MARCH 1, 2021 AT 8:30 A.M. ET PLANO, Texas, March 01, 2...
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Ba...
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has submitted a New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of chronic kidney disease (“CKD”) caused by Alport syndrome to the U.S. Food and Drug Administration (“FDA”). This NDA submission is based on the efficacy and safety data from the CARDINAL Phase 3 c...
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 202...
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021 PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on March 1, 2021. Reata’s management will host a conference call on March 1, 2021 at 8:30 am ET. The conference call will be accessible by di...
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock ...
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Offering PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,000,000 shares by the Company of its Class A common stock, at a price to the public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional shares of its Class A common stock, o...
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock ...
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced a public offering of 2,000,000 shares by the Company of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional shares of its Class A common stock, on the same terms and conditions a...
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Clas...
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the launch of a proposed underwritten public offering by the Company of 2,000,000 shares of its Class A common stock pursuant to an existing shelf registration statement. Reata intends to grant the underwriters a 30-day option to purchase 300,000 additional shares of its Class A common stock, on the same terms and conditions as...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.